Lee et al. analysed the clinical features of six patients harbouring EGFR-KRAS mutations and six patients with EGFR-ALK mutations, evidencing different morphological features of the tumours and behaviour to treatments [44]. This evidence concerns the gene EGFR and neoplasm.